

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

SECTION 1. IDENTIFICATION

Product name : Ribavirin Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 855 Leandro N. Alem St., 8 Floor
Buenos Aires, Argentina C1001AFB

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Acute toxicity (Oral) : Category 5

Germ cell mutagenicity : Category 2

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 3
single exposure

Specific target organ toxicity - : Category 1 (Blood)
repeated exposure (Oral)

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.
H335 May cause respiratory irritation.
H341 Suspected of causing genetic defects.
H360Df May damage the unborn child. Suspected of damaging fertility.

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

H372 Causes damage to organs (Blood) through prolonged or repeated exposure if swallowed.

Precautionary Statements

:

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P312 Call a POISON CENTER/ doctor if you feel unwell.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|--------------------|------------|-----------------------|
| Ribavirin | 36791-04-5 | >= 50 -< 70 |
| Cellulose | 9004-34-6 | >= 10 -< 20 |
| Magnesium stearate | 557-04-0 | >= 1 -< 5 |

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

| | | |
|---|---|--|
| In case of eye contact | : | Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. If in eyes, rinse well with water. |
| If swallowed | : | Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : | Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May be harmful if swallowed. May cause respiratory irritation. Suspected of causing genetic defects. May damage the unborn child. Suspected of damaging fertility. Causes damage to organs through prolonged or repeated exposure if swallowed. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : | Treat symptomatically and supportively. |

SECTION 5. FIRE-FIGHTING MEASURES

| | | |
|--|---|---|
| Suitable extinguishing media | : | Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical |
| Unsuitable extinguishing media | : | None known. |
| Specific hazards during fire fighting | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides Metal oxides |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. |

SECTION 6. ACCIDENTAL RELEASE MEASURES

| | | |
|----------------------------------|---|------------------------------------|
| Personal precautions, protection | : | Use personal protective equipment. |
|----------------------------------|---|------------------------------------|

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

- | | | |
|---|---|---|
| tive equipment and emergency procedures | : | Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : | Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | : | Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

SECTION 7. HANDLING AND STORAGE

- | | | |
|-------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. |

Ribavirin Solid Formulation

Version 4.2 Revision Date: 14.04.2025 SDS Number: 412740-00021 Date of last issue: 30.09.2023
 Date of first issue: 11.12.2015

- Conditions for safe storage : Take care to prevent spills, waste and minimize release to the environment.
 : Keep in properly labeled containers.
 : Store locked up.
 : Keep tightly closed.
 : Keep in a cool, well-ventilated place.
 : Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 : Strong oxidizing agents
 : Self-reactive substances and mixtures
 : Organic peroxides
 : Explosives
 : Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--|------------|--|--|----------|
| Ribavirin | 36791-04-5 | Wipe limit | 400 µg/100 cm ² | Internal |
| | | TWA | 40 µg/m ³ (OEB 3) | Internal |
| Cellulose | 9004-34-6 | CMP | 10 mg/m ³ | AR OEL |
| | | TWA | 10 mg/m ³ | ACGIH |
| Magnesium stearate | 557-04-0 | CMP | 10 mg/m ³ | AR OEL |
| Further information: A4 - Not classifiable as a human carcinogen | | | | |
| | | TWA (Inhalable particulate matter) | 10 mg/m ³ | ACGIH |
| | | TWA (Respirable particulate matter) | 3 mg/m ³ | ACGIH |

- Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 : Minimize open handling.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

| | | |
|--------------------------|---|--|
| Remarks | : | Consider double gloving. |
| Eye protection | : | Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Skin and body protection | : | Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

| | | |
|--|---|---|
| Appearance | : | powder |
| Color | : | white |
| Odor | : | No data available |
| Odor Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | No data available |
| Evaporation rate | : | Not applicable |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

| | | |
|--|---|--|
| Vapor pressure | : | Not applicable |
| Relative vapor density | : | Not applicable |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) | | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Autoignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity | | |
| Viscosity, kinematic | : | Not applicable |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Particle characteristics | | |
| Particle size | : | No data available |

SECTION 10. STABILITY AND REACTIVITY

| | | |
|------------------------------------|---|--|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents. |
| Conditions to avoid | : | Heat, flames and sparks. Avoid dust formation. |
| Incompatible materials | : | Oxidizing agents |
| Hazardous decomposition products | : | No hazardous decomposition products are known. |

SECTION 11. TOXICOLOGICAL INFORMATION

| | | |
|--|---|--|
| Information on likely routes of exposure | : | Inhalation Skin contact Ingestion Eye contact |
|--|---|--|

Acute toxicity

May be harmful if swallowed.

Product:

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

Acute oral toxicity : Acute toxicity estimate: 2.249 mg/kg
Method: Calculation method

Components:**Ribavirin:**

Acute oral toxicity : LD50 (Rat): 4.116 - 5.584 mg/kg
LD50 (Mouse): > 10.000 mg/kg
LD50 (Dog): >= 1.500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 1.554 - 1.758 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): 1.268 mg/kg
Application Route: Intraperitoneal

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Ribavirin:**

Remarks : No data available
May irritate skin.

Magnesium stearate:

Species : Rabbit

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

| | | |
|---------|---|--------------------------------------|
| Result | : | No skin irritation |
| Remarks | : | Based on data from similar materials |

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Ribavirin:**

| | | |
|---------|---|---|
| Remarks | : | No data available May irritate eyes. |
|---------|---|---|

Magnesium stearate:

| | | |
|---------|---|--------------------------------------|
| Species | : | Rabbit |
| Result | : | No eye irritation |
| Remarks | : | Based on data from similar materials |

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Ribavirin:**

| | | |
|---------|---|-------------------|
| Remarks | : | No data available |
|---------|---|-------------------|

Magnesium stearate:

| | | |
|--------------------|---|--------------------------------------|
| Test Type | : | Maximization Test |
| Routes of exposure | : | Skin contact |
| Species | : | Guinea pig |
| Method | : | OECD Test Guideline 406 |
| Result | : | negative |
| Remarks | : | Based on data from similar materials |

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:**Ribavirin:**

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | | Test Type: In vitro mammalian cell gene mutation test Test system: Rodent cell line Result: positive |
| | | Test Type: Chromosomal aberration Test system: Human lymphocytes |

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

Result: negative

Genotoxicity in vivo : Test Type: dominant lethal test
Species: Rat
Result: negative

Test Type: Mouse Lymphoma
Species: Mouse
Result: positive

Test Type: Micronucleus test
Species: Mouse
Result: positive

Germ cell mutagenicity - Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Ribavirin:**

Species : Mouse
Application Route : Oral
Exposure time : 6 Months

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

LOAEL : 75 mg/kg body weight
Result : negative
Target Organs : Blood, Testes
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 10 mg/kg body weight
Result : negative
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Mouse
Application Route : Oral
Exposure time : 18 Months
Result : negative
Remarks : The mechanism or mode of action may not be relevant in humans.

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:**Ribavirin:**

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Intraperitoneal injection
Fertility: LOAEL: < 20 mg/kg body weight
Symptoms: Reduced fertility
Result: positive

Test Type: Fertility
Species: Mouse, male
Application Route: Oral
Fertility: LOAEL: 35 mg/kg body weight
Symptoms: Reduced fertility
Result: positive

Test Type: Fertility
Species: Rat, females
Application Route: Oral
Fertility: NOAEL: 10 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 160 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development
Species: Rat, female
Application Route: Oral
Developmental Toxicity: LOAEL: \leq 1 mg/kg body weight
Symptoms: Reduced body weight, Reduced number of viable fetuses., Skeletal malformations.
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development
Species: Rabbit, female
Application Route: Oral
General Toxicity Maternal: LOAEL: 1 mg/kg body weight
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Symptoms: Reduced body weight, Skeletal malformations.
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development
Species: Hamster
Application Route: Oral
Developmental Toxicity: LOAEL: 2,5 mg/kg body weight
Symptoms: Skeletal and visceral variations ., Total Resorptions / resorption rate.
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: 0,3 mg/kg body weight
Embryo-fetal toxicity.: LOAEL: 1 mg/kg body weight
Symptoms: Skeletal malformations.
Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

May cause respiratory irritation.

Components:**Ribavirin:**

Assessment : May cause respiratory irritation.

STOT-repeated exposure

Causes damage to organs (Blood) through prolonged or repeated exposure if swallowed.

Components:**Ribavirin:**

Routes of exposure : Ingestion
Target Organs : Blood
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Ribavirin:**

Species : Monkey
LOAEL : 30 mg/kg
Exposure time : 10 d
Target Organs : Blood, Gastrointestinal tract

Species : Rat
NOAEL : 7,6 mg/kg
Application Route : Inhalation
Exposure time : 90 d
Target Organs : Blood, Lungs

Species : Dog

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

| | | |
|-------------------|---|-------------------------------|
| NOAEL | : | 5 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 1 y |
| Target Organs | : | Blood, Gastrointestinal tract |
| Species | : | Mouse |
| NOAEL | : | 20 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 18 Months |
| Target Organs | : | Blood, Cardio-vascular system |

Cellulose:

| | | |
|-------------------|---|----------------|
| Species | : | Rat |
| NOAEL | : | >= 9.000 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |

Magnesium stearate:

| | | |
|-------------------|---|--------------------------------------|
| Species | : | Rat |
| NOAEL | : | > 100 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |
| Remarks | : | Based on data from similar materials |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Ribavirin:**

| | | |
|--------------|---|--|
| Inhalation | : | Symptoms: Headache, Dizziness Remarks: Based on Human Evidence |
| Skin contact | : | Remarks: May cause eye irritation. Based on Human Evidence |
| Eye contact | : | Remarks: May cause eye irritation. Based on Human Evidence |
| Ingestion | : | Symptoms: blood effects, immune system effects, anorexia, Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver function change, Gastrointestinal disturbance |

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Ribavirin:**

| | | |
|-------------------------------|---|---|
| Toxicity to fish | : | LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l Exposure time: 96 h |
| Toxicity to daphnia and other | : | EC50 (Daphnia magna (Water flea)): > 117 mg/l |

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

- | | | |
|---|---|--|
| aquatic invertebrates | : | Exposure time: 48 h Method: OECD Test Guideline 202 |
| Toxicity to algae/aquatic plants | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 119 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 6,9 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 |
| Toxicity to microorganisms | : | EC50: > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 |
| Cellulose: | | |
| Toxicity to fish | : | LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials |
| Magnesium stearate: | | |
| Toxicity to fish | : | LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials |
| Toxicity to daphnia and other aquatic invertebrates | : | EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility. |
| Toxicity to algae/aquatic plants | : | EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility. NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials |
| Toxicity to microorganisms | : | EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction |

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials**Bioaccumulative potential****Components:****Ribavirin:**

Partition coefficient: n-octanol/water : log Pow: 0,971

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

| | |
|------------------------|---|
| Waste from residues | : Do not dispose of waste into sewer. Dispose of in accordance with local regulations. |
| Contaminated packaging | : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

| | |
|---------------|--------------|
| Revision Date | : 14.04.2025 |
| Date format | : dd.mm.yyyy |

Further informationSources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>**Full text of other abbreviations**

| | |
|--------|---|
| ACGIH | : USA. ACGIH Threshold Limit Values (TLV) |
| AR OEL | : Argentina. Occupational Exposure Limits |

| | |
|--------------|---------------------------------|
| ACGIH / TWA | : 8-hour, time-weighted average |
| AR OEL / CMP | : TLV (Threshold Limit Value) |

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Con-

Ribavirin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 4.2 | 14.04.2025 | 412740-00021 | Date of first issue: 11.12.2015 |

centration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8